Oncology Intelligence — July 21, 2026
|
Novartis’s up-to-$1.5 billion Myricx Bio buyout finally commits the radioligand-focused drugmaker to antibody-drug conjugates, wagering on a novel NMT-inhibitor payload engineered to sidestep the resistance dogging today’s topoisomerase-1 and tubulin ADCs.
Today’s top developments:
|
What to Watch
- Tempus–Personalis integration — Watch for Tempus AI to announce pharma co-development partnerships leveraging Personalis’ NeXT Personal for MRD-endpoint oncology trials within the next 12 months as integration accelerates.
- Isatuximab on-body launch — Q3 2026 uptake metrics will show whether the subcutaneous on-body injector meaningfully shifts anti-CD38 share or Darzalex’s formulary lock-in proves insurmountable.
- Kaveri Therapeutics disclosure — The Lupin oncology spinout still needs to name its two clinical-phase cancer asset targets and Phase timelines to attract US venture capital before the funding window narrows.
- Gynecologic ADC dealmaking — The $110B women’s oncology projection should drive BD competition for ovarian and cervical cancer assets through 2027, with gap-filling gynecologic ADC licensing deals the likeliest near-term catalysts.
This brief highlights the edition’s top stories. Read the full July 21, 2026 edition → for all stories and analysis — or browse the Oncology archive.